Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$13.44 USD
-0.39 (-2.82%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $13.43 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DNLI 13.44 -0.39(-2.82%)
Will DNLI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Other News for DNLI
Denali Therapeutics' CMO Joins Royalty Pharma Board | DNLI Stock News
Royalty Pharma appoints Ho, Weatherman to board of directors
Denali noted no FDA panel meeting in call with William Blair
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License ...
Denali Therapeutics Inc (DNLI) Announces FDA Priority Review for Tividenofusp Alfa | DNLI stock news